https://www.selleckchem.com/products/grl0617.html
Middle meningeal artery embolization (MMAE) has been used as an effective minimally invasive treatment for chronic subdural hematoma (cSDH). The demographics and clinical outcomes after MMAE treatment for cSDH have not yet been studied using a national database. We queried all MMAE cases up to October 7, 2020, from the TriNetX Analytics Network. We identified patients 18 years old who underwent MMAE for treatment of cSDH. Patient demographics, baseline characteristics, comorbidities, and clinical outcomes were evaluated within 180 d
Curtir
Comentario
Compartilhar
